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Background: This multicenter, open-label, phase Ib study was designed to assess the safety, 
pharmacokinetics and preliminary efficacy of ME-344, a mitochondrial inhibitor, administered in 
combination with the topoisomerase I inhibitor, topotecan, in patients with previously treated, 
locally advanced or metastatic small cell lung (SCLC), ovarian and cervical cancers.  
Patients and methods: In Part 1, patients received ME-344 10 mg/kg intravenously weekly on 
days 1, 8, 15 and 22 in combination with topotecan 4 mg/m2 on days 1, 8, and 15 of a 28 day 
cycle.  Cycles were repeated until disease progression or unacceptable toxicity. Patients were 
evaluated for dose-limiting toxicity (DLT) in cycle 1 and ME-344 pharmacokinetic samples were 
obtained.  In Part 2, patients with locally advanced or metastatic SCLC and ovarian cancer were 
enrolled in expansion cohorts treated at the recommended phase II dose (RP2D) determined in 
Part 1. 
Results: Fourteen patients were enrolled in Part 1 and no DLTs were observed.  The RP2D of 
ME-344 in combination with topotecan was established as 10 mg/kg.  In Part 2, 32 patients were 
enrolled.  The most common treatment-emergent all-grade and grade 3/4 toxicities included 
fatigue (65.2%, 6.5%), neutropenia (56.5%, 43.5%) and thrombocytopenia (50%, 23.9%). One 
patient with recurrent ovarian cancer experienced a partial response by RECIST 1.1 and 21 
patients achieved stable disease as best response.  
Conclusions: The combination of ME-344 10 mg/kg weekly and topotecan 4 mg/m2 was 
tolerable, however, the degree of anti-cancer activity does not support further investigation of the 




The development of resistance to chemotherapy remains a major obstacle in the development of 
cancer therapies [10].  Resistance to chemotherapy-induced caspase-dependent cell death or 
apoptosis, has been described in multiple cancers [7].  One strategy to circumvent resistance to 
chemotherapy-induced apoptosis is through the exploitation of caspase-independent cell death 
pathways.  NV-128 and active metabolite ME-344 are novel isoflavone derivatives that induce 
caspase-independent cell death by promoting mitochondrial depolarization and mTOR inhibition 
[1, 2, 9].  These agents are promising combination partners with chemotherapy to enhance 
response. 
 
ME-344 is a synthetic small molecule with an isoflavan ring structure, arising from metabolic 
demethylation of a first generation compound, NV-128 [1, 2]. ME-344 has overall similar 
biological and pharmacological properties to NV-128, however, exhibits more robust preclinical 
activity [2]. While the specific targets of NV-128 and ME-344 remain to be elucidated, exposure 
to these compounds in vitro results in a rapid decline in mitochondrial ATP production and the 
accumulation of mitochondrial superoxide (ROS) [1, 2].  These events in turn result in the 
activation of the MEK/ERK/Bax axis, the loss of mitochondrial membrane potential and mTOR 
pathway inhibition [1, 2].  The end result of NV-128 or ME-344 exposure in sensitive cancer cell 
line models is autophagic cell death and caspase-independent DNA fragmentation [1, 2]. NV-128 
induces cell death in vitro in epithelial ovarian cancer cell lines, including chemotherapy-resistant 
models and ovarian cancer stem cells [1, 2].   ME-344 is cytotoxic to leukemia and lung cancer 
cell lines in vitro and demonstrates anti-tumor activity in leukemia xenograft models [8, 11]. 
 
A first-in-human phase I study of ME-344 was conducted in patients with advanced solid tumors 
and the recommended phase II dose (RP2D) was 10 mg/kg administered intravenously (IV) 
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weekly [3]. The principal dose limiting toxicity (DLT) was grade 3 or higher peripheral 
neuropathy observed at an unacceptable frequency at doses > 10 mg/kg [3]. Promising anti-tumor 
activity was observed in this study with 5 patients experiencing prolonged stable disease (31-52 
weeks) and a single patient diagnosed with small cell lung cancer (SCLC) experienced a durable 
partial response lasting 52 weeks [3].  ME-344 is thought to be synergistic with chemotherapy, 
including the DNA-topoisomerase I inhibitor topotecan. Topotecan is an S-phase specific 
chemotherapy agent that inhibits DNA-topoisomerase I and is approved for the treatment of 
advanced ovarian cancer, cervical cancer and SCLC [6, 13] [5].  Traditionally, topotecan has been 
administered IV daily x 5 days every 21 days, however, in epithelial ovarian cancer similar 
efficacy has been reported with weekly IV administration days 1, 8 and 15 every 28 days [14, 15].  
Additionally, weekly topotecan has a more favorable safety profile with a lower incidence of 
grade 3 or 4 toxicity and less myelosuppression, supporting the choice of this schedule for 
combination with ME-344 [14, 15].  
 
This Phase Ib study enrolled patients with locally advanced or metastatic SCLC, ovarian cancer 
and cervical cancer.  Part 1 of this study was designed to evaluate the safety and tolerability of 
ME-344 administered IV weekly in combination with weekly topotecan and to determine the 
RP2D of ME-344 in this combination.  The pharmacokinetic (PK) profile of ME-344 in this 
combination was also investigated.  In Part 2, enrollment was restricted to patients with locally 
advanced or metastatic, previously treated SCLC and ovarian cancer to assess efficacy of the 
combination.  
 
Materials and Methods 
Patient Selection 
Eligible patients in Part 1 had locally advanced or metastatic SCLC, ovarian cancer or cervical 
cancer.  Patients with SCLC or ovarian cancer must have failed initial therapy and received up to 
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4 prior regimens of therapy.  Patients with cervical cancer had advanced disease not amenable to 
curative surgery and/or radiation therapy and received up to 4 prior regimens of therapy.  In Part 
2, enrollment was restricted to SCLC and ovarian cancer.  Patients had evaluable or measurable 
disease by RECIST (Response Evaluation Criteria in Solid Tumors) [16], a minimum life 
expectancy of 12 weeks, and an Eastern Cooperative Oncology Group (ECOG) performance 
status of 0-1.  Patients also had to be age 18 years or older with adequate hematopoietic, hepatic 
and kidney function.    Exclusion criteria included: previous treatment with irinotecan, topotecan 
or other topoisomerase I inhibitors; women who were pregnant or nursing; treatment with 
radiotherapy or immunotherapy or major surgery within 3 weeks; chemotherapy regimens, 
biologic or targeted therapies within 2 weeks; known central nervous system metastasis except 
for SCLC patients with previously treated CNS lesions stable for at least 4 weeks; uncontrolled 
infection or systemic disease; clinically significant cardiac disease not well controlled with 
medication or myocardial infarction within the last 12 months; neuropathy > grade 1; known 
hypersensitivity to any components of ME-344 or topotecan; known human immunodeficiency 
virus (HIV) or hepatitis B or C; history of solid organ transplant; and psychiatric disorder or 
social or geographic situation that would preclude study participation.      
 
Patients were recruited at 9 sites in the United States and the United Kingdom between April 
2014 and May 2015. The institutional review boards of participating institutions approved the 
protocol and written informed consent was obtained for all patients prior to performing study-
related procedures in accordance with federal and institutional guidelines.   
 
Study Design 
In part 1, ME-344 was administered at 10 mg/kg IV over 30 minutes on days 1, 8, 15, and 22 
every 28 days in combination with topotecan 4 mg/m2 over 30 minutes on days 1, 8 and 15 every 
28 days to a safety cohort of 12 patients.  The starting dose of ME-344 in this combination was 
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chosen based on the previously determined single-agent RP2D and non-overlapping toxicity with 
topotecan.  The cohort initially enrolled 6 patients with a safety review occurring after the 
completion of the first 28-day cycle by all patients.  A second safety review occurred after all 12 
patients completed one cycle of treatment. The starting dose of ME-344 was considered not 
tolerated if the observed rate of DLT in at least 6 patients was > 33%. Patients were considered 
evaluable if they received at least 2 doses of ME-344 and topotecan in the first cycle. An 
exception to this was patients requiring dose modification or discontinuation in cycle 1 due to 
treatment-related toxicity who were considered evaluable regardless of the number of doses 
received. In Part 2, expansion cohorts enrolled up to 20 patients each with SCLC and ovarian 
cancer at the RP2D of ME-344 in combination with topotecan as determined in Part 1.    
 
Patients were evaluated for efficacy approximately every 8 weeks for the first 6 cycles and then 
every 12 weeks.  Patients with stable disease or better by RECIST 1.1 continued to receive ME-
344 and topotecan for subsequent cycles until progressive disease, unacceptable toxicity or 
withdrawal of consent.  Patients who could no longer tolerate topotecan were allowed to continue 
to receive ME-344 alone.  One dose reduction was permitted for each agent due to unacceptable 
toxicity.  Premedication with anti-emetics was allowed according to standard practice guidelines.  
Ondansetron was to be used with caution due to the possible risk of QT prolongation.  
 
Safety Monitoring 
Before the initiation of study treatment, patients underwent a physical examination, ECOG 
performance status and 12-lead electrocardiogram (ECG).  Laboratory assessments included:  
complete blood count; serum chemistry including glucose, blood urea nitrogen (BUN), creatinine, 
sodium, potassium, chloride, calcium, carbon dioxide (CO2), alkaline phosphatase, aspartate 
aminotransferase, alanine aminotransferase, total bilirubin, total protein, albumin, and lactate 
dehydrogenase; urinalysis; and serum pregnancy test for women of child-bearing potential. Safety 
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assessments during study treatment in patients in both Parts 1 and 2 included physical 
examination, ECG and laboratory assessments.  Adverse events were assessed using the National 
Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.  
DLT was defined as any of the following events assessed as related to study drug:  > grade 3 
neutropenia lasting > 5 days or accompanied by fever, febrile neutropenia, grade 4 
thrombocytopenia, or grade 3 thrombocytopenia associated with bleeding; > grade 3 abnormal lab 
values (except neutropenia and thrombocytopenia) assessed as clinically significant; > grade 3 
non-laboratory toxicity (excluding alopecia, rash, nausea, diarrhea, and vomiting if controlled 
with standard supportive therapy); any treatment related toxicity requiring study drug interruption 
or dose reduction during cycle 1.   
 
Pharmacokinetic Assessments 
ME-344 drug levels were measured in patients enrolled in Part 1 during cycle 1 at the following 
time points: on day 1 pre-infusion, just prior to the end of infusion, 0.5, 1, 2, 4, 6 and 24 hours 
post-ME-344 dosing; on day 15 pre-infusion and just prior to the end of infusion.   
   
Statistical Analysis 
Descriptive statistics were used for baseline characteristics, safety assessments and tumor 
response. Descriptive statistics for ME-344 PK concentrations and PK parameters were generated 
using Phoenix® WinNonlin®, Version 6.3. Estimation of the PK parameters was performed by 
noncompartmental methods.  All patients who received at least one dose of ME-344 were 
included in the safety analysis.  The efficacy population included all patients with measureable 
disease at baseline and who completed at least 1 cycle of treatment and underwent at least one 
follow-up tumor evaluation or who discontinued treatment prior to the first tumor evaluation due 
to disease progression. The planned total trial sample size of approximately 50 patients (Part 1 
and Part 2) was designed to evaluate the safety of the combination.  With a sample size of 50 and 
 8 
an observed grade 3/4 hematologic toxicity rate of 20% for ME-344 and topotecan combination, 
the upper 95% confidence interval excludes the doubling of the grade 3/4 hematologic toxicity 




Overall, 46 patients were enrolled in the study (14 in Part 1 and 32 in Part 2). Patient 
demographics and baseline characteristics are described in Table 1. The average age was 58 years 
old and ECOG performance status was 1 in 29 patients (63%) and 0 in 17 patients (37%). 
Twenty-eight patients (60.9%) had ovarian cancer receiving on average 3.1 prior lines of therapy 
(range 1-4); 13 patients (28.3%) had SCLC receiving on average 1.5 prior lines of therapy (range 
1-3); and 5 patients had cervical cancer (10.9%) receiving on average 2.8 prior lines of therapy 
(range 2-4). All patients received treatment with ME-344 and all but 1 patient received treatment 
with topotecan (97.8%).  Reasons for discontinuation of ME-344 were disease progression in 35 
patients (76.1%), an adverse event in 7 (15.2%), the subject’s decision to discontinue treatment in 
2 (4.3%), non-compliance with study drug in 1 (2.2%), and other reasons in 1 (2.2%). Reasons for 
discontinuation of topotecan were disease progression in 33 (71.7%), an adverse event in 8 
(17.4%), the subject’s decision to discontinue treatment in 2 (4.3%), non-compliance with study 
drug in 1 (2.2%), and other reasons in 1 (2.2%). 
 
RP2D Determination  
A total of 14 patients were enrolled in Part 1. No patients experienced DLT and ME-344 
administered at 10 mg/kg IV over 30 minutes on days 1, 8, 15, and 22 every 28 days was 
determined to be the RP2D in combination with topotecan 4 mg/m2 over 30 minutes on days 1, 8 




Patients receiving at least one dose of study drug were evaluable for the safety analysis (N=46).  
As the administered dose and schedule of ME-344 and topotecan was the same in Part 1 and Part 
2, the safety analysis included all patients.  All patients experienced at least 1 adverse event (AE) 
and 43 patients (93.5%) experienced an AE considered related to ME-344 by the study 
investigators.  The most frequent all-grade and grade 3/4 treatment-emergent AEs regardless of 
attribution were fatigue (65.2%, 6.5%), neutropenia (56.5%, 43.5%), thrombocytopenia (50%, 
23.9%), nausea (47.8%, 0%), diarrhea (45.7%, 4.3%), decreased appetite (41.3%, 0%) and 
hypertension (41.3%, 32.6%) (Table 2).  Grade 3/4 treatment-emergent AEs reported in at least 3 
patients regardless of attribution also included anemia (N=9, 19.6%), hypokalemia (N=4, 8.7%), 
decreased white blood cell count (N=3, 6.5%), febrile neutropenia (N=3, 6.5%) and small 
intestinal obstruction (N=3, 6.5%).  The incidence of peripheral neuropathy was very low in this 
patient cohort (N=2, 4.3%) and no grade 3/4 peripheral neuropathy events were observed.  
Infusion reactions related to ME-344 occurred in 4 patients (8.7%), including 1 grade 3 event 
resulting in treatment discontinuation. Hypertension occurred in 21 patients (45.7%) including 15 
patients (32.6%) with grade 3 hypertension.  The mean duration of ME-344 treatment was 3.4 
cycles.  The maximum duration of therapy was 14 cycles (N=1).  The relative dose intensity of 
ME-344 as defined as the percentage of the actual dose delivered relative to the intended dose 
was 85.4%.  ME-344 and topotecan were discontinued due to an AE in 3 patients who 
experienced ME-344-related infusion reaction, bacteremia and neutropenic sepsis (one patient 
each).   
 
Seventeen patients (37%) experienced a total of 23 serious adverse events (SAEs) while on study.  
This included 1 patient enrolled in Part 2 with grade 3 diarrhea related to ME-344 and grade 4 
thrombocytopenia and febrile neutropenia related to topotecan during the first treatment cycle.  
An additional 5 patients experienced 6 SAEs related to topotecan.  This included one patient each 
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with: grade 4 thrombocytopenia during cycle 1, grade 3 fatigue during cycle 2, grade 3 febrile 
neutropenia during cycle 1 and 1 patient with both grade 3 bloodstream infection caused by an 
extended spectrum beta lactamase (ESBL)-producing bacteria and bacteremia during cycle 5.  
One patient with SCLC had a fatal event of neutropenic sepsis during cycle 4 of therapy assessed 
by the investigator as related to topotecan. An additional 5 patients (10.9%) in the safety 
population died due to progressive disease within 30 days of treatment discontinuation.  
 
Pharmacokinetics 
Samples from 13 patients enrolled in Part 1 were available for PK analysis during cycle 1 on days 
1 and 15.  Samples were analyzed for plasma ME-344 with a lower limit of quantification of 1.00 
ng/mL and PK parameters are summarized in Table 3. Maximal ME-344 plasma concentrations 
were observed at the end of the 30-minute infusion. The peak and extent of exposure parameter 
values were:  Cmax of 20,880 ng/mL and AUC0-t and AUC0-inf of 21,830 and 22,040 ng*hr/mL, 
respectively. Mean terminal half-life was 5.3 hours. Upon visual inspection of the mean AUC 
profile, ME-344 plasma levels declined in a multi-exponential manner on Day 1, and the end-of-
infusion concentration on Day 15 was approximately 27% lower than on Day 1, suggesting no 
accumulation of the drug (Figure 1). Mean total body clearance and total volume of distribution 
adjusted for patients’ body weight were 0.505 L/hr and 1.2 L, respectively. 
 
Efficacy 
Forty-one patients were evaluable for efficacy (Table 4).  The median time on study was 3.4 
cycles.  One patient with recurrent ovarian cancer achieved a partial response (PR) and remained 
on study for 14 cycles.  In addition, 21 patients experienced stable disease (SD) as their best 
response, of which 9 patients (22%) had SD lasting for at least 12 weeks.  The overall response 
rate was 2.4% and the clinical benefit rate (CR+PR+SD) was 53.7%. Study enrollment was 
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stopped in Part 2 due to lack of efficacy for the combination of ME-344 and topotecan, as 
compared to historical controls with topotecan alone.   
 
Discussion 
The combination of ME-344 and topotecan administered once weekly was well tolerated in 
patients with locally advanced or metastatic SCLC, ovarian cancer and cervical cancer.  The 
toxicity profile of the combination was consistent with that of topotecan monotherapy when 
administered on a weekly schedule [14, 15].  The most common treatment-emergent adverse 
events were fatigue, neutropenia, thrombocytopenia, nausea and diarrhea. No DLTs were 
observed with the combination of ME-344 and weekly topotecan at the doses evaluated in this 
study and the RP2D of ME-344 in combination with weekly topotecan was determined to be 10 
mg/kg IV weekly.  A modest degree of efficacy for the combination was observed with an overall 
response rate of 2.4% and a clinical benefit rate of 53.7%.  While this study is somewhat limited 
due to sample size and a mixed patient population, the degree of efficacy was similar to historical 
controls of topotecan weekly as a single agent [15].   
 
Although the toxicity profile of the combination was driven mostly by known topotecan-related 
adverse events, we observed a higher than expected rate of hypertension. In fact, hypertension 
occurred in 45.7% of patients, including 32.6% with grade 3 hypertension. The timing of onset of 
hypertension was during the ME-344 infusion or shortly thereafter for many patients in this study.  
One similar event was observed in the first-in-human Phase I trial of ME-344 where a patient 
experienced grade 3 hypertension and bradycardia during the infusion [3]. The mechanism of this 
is unclear, however, can by hypothesized to occur as a result of ME-344 treatment-induced 
accumulation of mitochondrial superoxide (ROS).  Increased ROS production has been associated 
with hypertension and evidence supports increased ROS as a mechanism of angiotensin II 
mediated hypertension [4].  The potential for treatment-induced hypertension should be 
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considered when designing future clinical trials of ME-344.  Of note, neurotoxicity was not 
observed with ME-344 at a dose of 10 mg/kg IV weekly, validating the conclusions of the Phase I 
trial of ME-344 where peripheral neuropathy was a DLT only observed at doses of 15-20 mg/kg 
IV weekly [3]. 
 
The combination of ME-344 and topotecan failed to reach the threshold of promising efficacy, 
however, other rational combination strategies with ME-344 should be explored.  ME-344 
inhibits in vivo mitochondrial respiration, however, this therapeutic intervention may not result in 
meaningful tumor growth inhibition if tumors are primarily using aerobic glycolysis for 
macromolecule biosynthesis [12].  Emerging data support the hypothesis that normalization of the 
tumor vasculature with anti-angiogenic therapies leads to a decrease in aerobic glycolysis and an 
increase in mitochondrial respiration [12].  The addition of ME-344 to anti-angiogenic tyrosine 
kinase inhibitors results in synergistic tumor growth inhibition in xenograft models of breast and 
lung cancer and this strategy is currently being investigated in a Phase Ib trial of ME-344 in 
combination with antiangiogenic therapy (NCT02806817). Additional studies should incorporate 
pharmacodynamic biomarker testing to investigate mTOR and mitochondrial metabolism 











The authors would like to thank the patients and their families for their participation in this study, 
as well as the study staff, and the Sarah Cannon Research Institute for managing the study.  
 
Compliance with Ethical Standards 
This study was conducted according to ICH guidelines and all sites had IRB/EC approval prior to 
enrolling patients. 
 
Funding   
This study was funded by MEI Pharma, Inc. 
 
Conflict of Interest 
Jennifer R. Diamond, Barbara Goff, Carolyn D. Britten, Michael S. Gordon, Hani Gabra, David 
M. Waterhouse, D. Ross Camidge, and Erika P. Hamilton report no potential conflict of interest.  
Mark Poole is an employee of MEI Pharma. Kathleen M. Moore reports advisory boards for: 
Astra Zeneca, Advaxis, Clovis, Immunogen, Genentech/Roche and VBL Therapeutics, and 
Steering Committees for: Advaxis and Astra Zeneca. Johanna C. Bendell reports research funding 
from Gilead, Genentech, BMS, Five Prime, Lilly, Merck, Medimmune, Celgene, EMD Serono, 
Taiho, Macrogenetics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, Astrazeneca, BI, 
Baiichi Sankyo, Bayer, Incyte, Apexigen, Roche, Koltan, SynDevRx, Forty Seven, Abbvie, 
StemCentrix, Array, Agios, ARMO, and CytoMx.  Martin D. Forster is supported by the 
UCL/UCLH NIHR Biomedical Research Centre. 
 
Informed Consent 







1. Alvero AB, Montagna MK, Chen R et al. (2009) NV-128, a novel isoflavone 
derivative, induces caspase-independent cell death through the 
Akt/mammalian target of rapamycin pathway. Cancer 115:3204-3216 
2. Alvero AB, Montagna MK, Holmberg JC et al. (2011) Targeting the 
mitochondria activates two independent cell death pathways in ovarian 
cancer stem cells. Mol Cancer Ther 10:1385-1393 
3. Bendell JC, Patel MR, Infante JR et al. (2015) Phase 1, open-label, dose 
escalation, safety, and pharmacokinetics study of ME-344 as a single agent in 
patients with refractory solid tumors. Cancer 121:1056-1063 
4. Dikalova AE, Bikineyeva AT, Budzyn K et al. (2010) Therapeutic targeting of 
mitochondrial superoxide in hypertension. Circ Res 107:106-116 
5. Hertzberg RP, Caranfa MJ, Hecht SM (1989) On the mechanism of 
topoisomerase I inhibition by camptothecin: evidence for binding to an 
enzyme-DNA complex. Biochemistry 28:4629-4638 
6. Hirte H, Kennedy EB, Elit L et al. (2015) Systemic therapy for recurrent, 
persistent, or metastatic cervical cancer: a clinical practice guideline. Curr 
Oncol 22:211-219 
7. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to 
apoptosis. Nat Rev Cancer 2:277-288 
8. Jeyaraju DV, Hurren R, Wang X et al. (2016) A novel isoflavone, ME-344, 
targets the cytoskeleton in acute myeloid leukemia. Oncotarget 
9. Lim SC, Carey KT, Mckenzie M (2015) Anti-cancer analogues ME-143 and 
ME-344 exert toxicity by directly inhibiting mitochondrial NADH: ubiquinone 
oxidoreductase (Complex I). American journal of cancer research 5:689-701 
10. Lopez JS, Banerji U (2016) Combine and conquer: challenges for targeted 
therapy combinations in early phase trials. Nat Rev Clin Oncol 
11. Manevich Y, Reyes L, Britten CD et al. (2016) Redox Signaling and 
Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone 
ME-344. The Journal of pharmacology and experimental therapeutics 
358:199-208 
12. Navarro P, Bueno MJ, Zagorac I et al. (2016) Targeting Tumor Mitochondrial 
Metabolism Overcomes Resistance to Antiangiogenics. Cell reports 15:2705-
2718 
13. Riemsma R, Simons JP, Bashir Z et al. (2010) Systematic Review of topotecan 
(Hycamtin) in relapsed small cell lung cancer. BMC cancer 10:436 
14. Safra T, Berman T, Yachnin A et al. (2013) Weekly topotecan for recurrent 
ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and 
efficacy study--the Israeli experience. Int J Gynecol Cancer 23:475-480 
15. Sehouli J, Stengel D, Harter P et al. (2011) Topotecan Weekly Versus 
Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian 
Cancer: a randomized multicenter phase II trial of the North-Eastern German 
 16 
Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 
29:242-248 
16. Therasse P, Arbuck SG, Eisenhauer EA et al. (2000) New guidelines to 
evaluate the response to treatment in solid tumors. Journal of the National 

















Age, years, mean (range) 50.6 (26, 72) 61.2 (36, 78) 58 (26, 78) 
Sex, n (%) 
     Female 










Race, n (%) 
     White  
     Asian    















Ethnicity, n (%) 







Primary tumor type, n (%) 
     Ovarian 
     SCLC 
     Cervical 














Prior lines of therapy, mean (range) 
     Ovarian 
     SCLC 











ECOG stage, n (%) 
     0 

















Table 2. Treatment-Emergent Adverse Events Occurring in > 15% of Patients  
 Number (%) of patients 
Total N=46 
Preferred Term Any grade Grade < 3 
Patients with any AE 46 (100) 39 (84.8) 
   
Fatigue 30 (65.2) 3 (6.5) 
Neutropenia 26 (56.5) 20 (43.5) 
Thrombocytopenia 23(50) 11 (23.9) 
Nausea 22 (47.8) 0 (0) 
Diarrhea 21 (45.7) 2 (4.3) 
Decreased appetite 19 (41.3) 0 (0) 
Hypertension 19 (41.3) 15 (32.6) 
Vomiting 18 (39.1) 0 (0) 
Anemia 16 (34.8) 9 (19.6) 
Constipation 15 (32.6) 0 (0) 
Weight decreased 9 (19.6) 0 (0) 
Arthralgia 8 (17.4) 0 (0) 
Back pain 8 (17.4) 0 (0) 
Dyspnea 8 (17.4) 2 (4.3) 
Abdominal pain 7 (15.2) 1 (2.2) 
Asthenia 7 (15.2) 0 (0) 







Table 3.  Pharmacokinetics of ME-344 
 
Pharmacokinetic Parameters Arithmetic Mean SD 
Cmax (ng/mL) 20880 8201.3 
Cmin (ng/mL) 25.30 12.824 
tmax (hr) 0.500 0.48, 2.02 
AUC0-t (hr*ng/mL) 21830 6565.4 
AUC0-inf (hr*ng/mL) 22040 6563 
AUC%extrap (%) 1.03 0.830 
t1/2 (hr) 5.301 2.0114 
kel (1/hr) 0.1440 0.039468 
CL,ss (L/hr) 42.593 33.4433 
Vd,ss (L) 104.648 121.4296 
CL,ss/kg (L/hr) 0.505 0.2450 




Table 4.  Summary of Disease Response 
Number (%) of Patients  
_____ ____________                    ________________________________________ 
Characteristic Part 1 (N=12) Part 2 (N=29) Total (N=41) 
 
Best Overall Response    
  Complete Response (CR) 0 0 0 
  Partial Response (PR)  1 (  8.3) 0  1 (  2.4) 
  Stable Disease (SD)  5 ( 41.7) 16 ( 55.2) 21 ( 51.2) 
  Progressive Disease (PD)  3 ( 25.0)  6 ( 20.7)  9 ( 22.0) 
  Not Evaluable  3 ( 25.0)  7 ( 24.1) 10 ( 24.4) 
 
Overall Response Rate (CR+PR)  1 (  8.3) 0  1 (  2.4) 
    
 
 
